Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.

Authors:
Su HX; Yao S; Zhao WF; Li MJ; Liu J and 19 more

Journal:
Acta Pharmacol Sin

Publication Year: 2020

DOI:
10.1038/s41401-020-0483-6

PMCID:
PMC7393338

PMID:
32737471

Journal Information

Full Title: Acta Pharmacol Sin

Abbreviation: Acta Pharmacol Sin

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"all data are shown as mean ? sd. table 2"

Code Sharing
Evidence found in paper:

"Competing interests The authors declare no competing interests."

Evidence found in paper:

"The authors sincerely thank Prof. Zi-he Rao and Prof. Hai-tao Yang for kindly providing the initial protein sample as well as substrate for the enzymatic assay of 3CLpro. We also thank the staff from beamlines BL17U1 and BL18U1 at Shanghai Synchrotron Radiation Facility. This work was supported by the National Key R&D Program of China (nos. 2020YFC0841400, 2017YFB0202604, and 2016YFA0502301), the National Natural Science Foundation of China (nos. 91953000 and 21877122), the International Partnership Program of Chinese Academy of Sciences (no. 153631KYSB20170043), Chinese Academy of Engineering and Jack Ma Foundation (no. 2020-CMKYGG-05), and Science and Technology Commission of Shanghai Municipality (no. 20431900200)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025